BIO Asia–Taiwan 2025 Exhibition Opens!

​BIO Asia–Taiwan 2025 Exhibition Opens!
Over 2,200 booths and 600 delegates from 50 countries gather to lead a new wave of biotech innovation in Asia
 
24 July, 2025
The BIO Asia–Taiwan 2025 Exhibition opened its doors today at the Taipei Nangang Exhibition Center, TaiNEX 1. With this year’s exhibition bigger than ever with 2,200 booths, BIO Partnering also registered a record 8,800 meetings scheduled. During today's official opening ceremony, two major honors were also presented: the 2025 BIO Asia Award and the 2025 Taiwan BIO Awards, recognizing excellence in this industry.
 
Chairman of BIO Asia–Taiwan Johnsee Lee stated in his opening remarks that this year’s event welcomes over 600 international delegates from 50 countries, including the United States, Japan, Canada, Belgium, Singapore, and South Korea, with more than 2,300 participants joining the gathering. Themed "Next Wave of Biotech Opportunities", this year’s conference has expanded in scale to feature three major forums: Innovation Forum, Investment Summit, and Regional Collaboration Forums.
 
Lee noted that the BIO Asia–Taiwan Conference has once again set new records in scale, featuring 40 sessions and over 180 speakers sharing insights on global innovation trends and challenges. On the exhibition side, the number of booths has reached a record 2,200, while 8,800 partnering meeting invitations were booked, highlighting the industry's strong energy and high level of participation.
 
Kelly Seagraves, Vice President of National Security and International Affairs at the US-based Biotechnology Innovation Organization (BIO), stated that BIO Asia–Taiwan is one of Asia’s premier gatherings for biotech leaders, innovators, and change-makers. She emphasized that the event reflects the remarkable growth momentum of the global life sciences sector. Whether supply chains or the commercialization of early-stage R&D, cross-border collaboration is an essential element of this industry. Taiwan, she noted, is positioned at the heart of this transformation. The co-hosting of BIO Asia–Taiwan by BIO and the Taiwan Bio Industry Organization (Taiwan BIO) is a prime example of international cooperation and industry integration.
 
Taiwan's Minister of Health and Welfare Chiu Tai-yuan remarked in his speech that BIO Asia–Taiwan has now become one of the world’s top three biotechnology conventions. He emphasized that Taiwan will continue to position itself as an innovation hub in Asia, focusing on three key areas: technological innovation, regional collaboration, and biotech investment. The government will continue to advance health equity and sustainable care, while deepening efforts in precision medicine, cancer and chronic disease prevention. Through developments in cell therapy, biologics, and smart medical devices, Taiwan aims to further enhance its global visibility and influence in medical technology.
 
Wu Cheng-wen, Minister of the National Science and Technology Council, stated that the Executive Yuan of the Taiwan government held a special discussion this morning on strategies to integrate semiconductors with industries such as healthcare and agriculture. Going forward, the government will build a comprehensive innovation platform to promote the development of fields including digital therapeutics, smart diagnostics, early cancer screening, and AI-assisted diagnosis. He expressed hope that Taiwan’s industries and its leaders will collaborate with the government to gradually build a national team that can contribute globally in biotech, healthcare, and agriculture.
 
Taiwan Premier Cho Jung-tai made a special appearance at the opening ceremony, stating that BIO Asia–Taiwan, as a major international gathering, can showcase to the world Taiwan’s potential in the medical and health sectors. He highlighted that Taiwan’s biotech companies have achieved a total revenue of NT$775 billion (US$26 billion), and several Taiwan-developed new drugs have successfully entered global markets, reflecting the country's growing influence in the international biotech arena.

Premier Cho Jung-tai noted that during the Executive Yuan meeting earlier that morning, Minister Wu Cheng-wen presented the “Taiwan Chip-based Industrial Innovation Program”, which aims to further integrate applications such as telecommunications, artificial intelligence, and Big Data to accelerate medical innovation, particularly in precision health and agriculture.

He also mentioned that President Lai Ching-te has established the “Healthy Taiwan Promotion Committee”, which is strengthening cancer screening efforts and has launched a NT$10 billion (US$340 million) fund for cancer drug development. The initiative also emphasizes genetic testing and precision medicine. In addition, the government plans to launch the Long-Term Care 3.0 plan next year. Premier Cho expressed hopes for global collaboration to advance industrial diversification and further enhance Taiwan’s international competitiveness in the healthcare and biotech sectors.

At the opening ceremony, Premier Cho Jung-tai, BIO Asia–Taiwan Chairman Johnsee Lee, and Taiwan Bio Industry Organization Chairman Lee-Cheng Liu were invited to present the 2025 BIO Asia Award and the 2025 Taiwan BIO Awards for Outstanding Biotech Industry Achievements, recognizing key contributors and innovators in the industry.
 
The 2025 BIO Asia Award honors individuals and organizations with outstanding contributions to Asia’s biotech industry. This year, the Individual Award was presented to Taiwan's Academician Chi-Huey Wong and Dr. Raul V. Destura from the Philippines, while Taiwan's Development Center for Biotechnology (DCB) received the Organization Award.
 
Taiwan BIO Award winners included 15 companies this year. Picking up the award for Outstanding Company were Standard Chem. & Pharm. (TW: 1720) and Grape King Bio (TW: 1707).
 
The Emerging Company award winners included Orient Pharma (TW: 4166), Genomics BioSci & Tech (TW: 4195), AP Biosciences (TW: 6945), Applied BioCode (TW: 6598), and Synbio Tech (TW: 1295).
 
The Outstanding Startup winners were HanchorBio (TW: 7827), JelloX Biotech, and Fecula Biotech.
 
The Innovation award went to five notable innovations:
REGENECYTE, HPC Cord Blood, from StemCyte (TW: 4178); Novel Dual Targeted Therapy for Glaucoma, from the Industrial Technology Research Institute (ITRI); FaceHeart Vitals™, from FaceHeart (TW: 3011); Precision Oriented Peptides POPs, from CH Biotech R&D (TW: 6534); and Kang Er Dong Pro and Prebiotics, from Grape King Bio.
 
These 15 companies took the stage to receive their awards.